Rhinomed Limited
(ASX:RNO) has announced that its current Phase 1 trial for its new nasal technology for the treatment of sleep apnoea is nearing completion.
The trial is being conducted on 18 to 20 patients at Monash Health.
The company expected the results to be finalised in early 2016, but now expects the final two patients to be recruited and for Monash Health to complete the study in the next six weeks.
The primary endpoints for the trial seek to confirm that moderate Obstructive Sleep Apnoea can be reduced with the Rhinomed device.
Rhinomed reported a net loss of $2.78 million at 31 December 2015.
